Recent Developments

Cerecor Announces Acquisition of TARP-γ8-AMPA Receptor Antagonist (CERC611) from Lilly

Cerecor Inc. (CERC), a clinical stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has acquired exclusive, worldwide rights from Eli Lilly and Company (“Lilly”) to … Continue reading

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

root9B Technologies Announces Dismissal of Class Action Lawsuit

root9B Technologies (RTNB) announced today that the United States District Court for the District of Colorado has dismissed, with prejudice, the securities class action litigation originally filed in June 2015 against root9B Technologies and certain of the Company’s officers and … Continue reading

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC301 as an Oral, Adjunctive Treatment of Major Depressive Disorder

Cerecor Inc. (CERC), a clinical stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC301, … Continue reading

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

Diffusion Pharmaceuticals Successfully Completes Animal Toxicity Studies in Preparation for Phase 3 Pivotal Trial of TSC in New Diagnosed Glioblastoma Patients

Diffusion Pharmaceuticals Inc. (DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia related diseases, today reported the successful completion of dosing of two animal toxicology studies required by the … Continue reading

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

ContraFect Announces Organizational Changes

YONKERS, NY(Marketwired September 16, 2016) ContraFect Corporation (CFRX) (CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for lifethreatening, drugresistant infectious diseases, today announced…

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

Cerecor Inc. (CERC), a clinical stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has entered into a $15 million common stock purchase agreement (the “Agreement”) … Continue reading

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

Edge Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series and Participate in Additional Investor Conferences in September

Edge Therapeutics, Inc. (EDGE), a clinical stage biotechnology company developing novel hospital based therapies for the management of acute, life threatening conditions, today announced that President and Chief Executive Officer Brian A. Leuthner will participate in a fireside chat at … Continue reading

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC501 for Smoking Cessation

Cerecor Inc. (CERC), a clinical stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC501, … Continue reading

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

Edge Therapeutics Announces Additional Pharmacokinetic Data Supporting the Potential Clinical and Health Economic Impact of EG1962 in Aneurysmal Subarachnoid Hemorrhage

Edge Therapeutics, Inc. (EDGE) today announced additional positive pharmacokinetic data from the Phase 1/2 NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) study of its lead product candidate EG1962 for the treatment of patients who have … Continue reading

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

Edge Therapeutics to Present Additional Data from Phase 1/2 NEWTON Study of EG1962 at Two Scientific Conferences in September

Edge Therapeutics, Inc. (EDGE), a clinical stage biotechnology company developing novel hospital based therapies for the management of acute, life threatening conditions, today announced that additional data from its completed North American Phase 1/2 NEWTON (Nimodipine microparticles to Enhance recovery … Continue reading

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

Dan Wachtler Named President & COO of root9B Technologies

root9B Technologies (RTNB) today announced that Dan Wachtler has been named President and Chief Operating Officer (COO), effective immediately. Formerly, Mr. Wachtler was President and CEO of root9B Technologies’ IPSA subsidiary.

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off

root9B Technologies Announces Strategic Shift to Pure Cybersecurity

The Board of root9B Technologies (RTNB) has approved a series of actions that will shift the organization to a “pure play” cybersecurity company and will seek shareholder approval for a reverse stock split. Joe Grano, Chief Executive Officer of root9B … Continue reading

Posted in Recent Development News: Q3 - 2016, Recent Developments | Comments Off